The Endpoints 100 survey: Has biotech hit rock bottom?
There may be a solid chunk of executives in the Endpoints 100 who feel that better times are ahead for the biotech industry in 2024, but they’re still outnumbered by doubters and the undecided.
This H2 snapshot of the opinions of 100+ biotech execs — the large majority of CEOs — found many are still recruiting new workers, but only when absolutely necessary. The overall tone remains distinctly cautious in the wake of the post-pandemic plunge. Most CEOs — 70 responded to this set of questions — are not expecting to see deal terms improve much and shake their heads over the “poor” state of IPOs.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.